RECOMMENDATIONS In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2 , the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX , EndoPredict , PAM50 , Breast Cancer Index , and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer .
No biomarker except for estrogen receptor , progesterone receptor , and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens .
PURPOSE To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer .
Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
Background : A dichotomous index combining two gene expression assays , HOXB13 : IL17BR ( H : I ) and molecular grade index ( MGI ) , was developed to assess risk of recurrence in breast cancer patients . The study objective was to demonstrate the prognostic utility of the combined index in early-stage breast cancer . Methods : In a blinded retrospective analysis of 588 ER-positive tamoxifen-treated and untreated breast cancer patients from the r and omised prospect i ve Stockholm trial , H : I and MGI were measured using real-time RT – PCR . Association with patient outcome was evaluated by Kaplan – Meier analysis and Cox proportional hazard regression . A continuous risk index was developed using Cox modelling . Results : The dichotomous H : I+MGI was significantly associated with distant recurrence and breast cancer death . The > 50 % of tamoxifen-treated patients categorised as low-risk had <3 % 10-year distant recurrence risk . A continuous risk model ( Breast Cancer Index ( BCI ) ) was developed with the tamoxifen-treated group and the prognostic performance tested in the untreated group was 53 % of patients categorised as low risk with an 8.3 % 10-year distant recurrence risk . Conclusion : Retrospective analysis of this r and omised , prospect i ve trial cohort vali date d the prognostic utility of H : I+MGI and was used to develop and test a continuous risk model that enables prediction of distant recurrence risk at the patient level
RECOMMENDATIONS In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2 , the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX , EndoPredict , PAM50 , Breast Cancer Index , and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer .
No biomarker except for estrogen receptor , progesterone receptor , and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens .
PURPOSE To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer .